Developer docs
API playgroundTry for free, no card

Search company profiles

Eckert & Ziegler

Full company profile

uuid0003kqo

Namestring
Eckert & Ziegler
Legal namestring
Eckert & Ziegler SE
Websiteurl
ezag.com
Company typeenum
Public
Founded yearint
1998
Descriptiontext

Eckert & Ziegler SE is a Berlin-headquartered, TecDAX-listed (Deutsche Börse, ISIN DE0005659700) isotope technology group operating across medical, scientific, and industrial end-markets. The company's core capabilities span the radioisotope value chain — production of medical isotopes including Germanium-68, Gallium-68, Lutetium-177, Actinium-225, and Yttrium-90, alongside brachytherapy implants (I-125 prostate and ophthalmic seeds, Ru-106 eye applicators) and industrial radiometry products (Kr-85 thickness sources, Ni-63 detection sources, calibration sources). Its technology platform centers on a dedicated Alpha Laboratory in Berlin for Actinium-225, the proprietary GalliaPharm Ge-68/Ga-68 generator system, GMP-compliant radiopharmaceutical manufacturing suites, the Modular-Lab PharmTracer synthesis platform, and cyclotron-based production at the Berlin-Buch, Braunschweig, and Jintan (China, via 50:50 JV QKM with DC Pharma) sites.

The business generates revenue through three primary streams: (i) one-time sales of isotope products to pharmaceutical companies, hospitals, and research institutions; (ii) contract development and manufacturing (CDMO) services for radiopharmaceuticals, supplied under quote-based B2B contracts to clients including Molecular Partners, SK Biopharmaceuticals, Ariceum, Bicycle Therapeutics, Telix, and PentixaPharm; and (iii) hardware sales of brachytherapy devices and industrial radiometry products. Go-to-market is enterprise field sales complemented by industry engagement such as the annual Boston Radionuclide Theranostics Forum. The customer base is horizontally segmented into pharmaceutical/biotech companies (primary), nuclear medicine departments and hospitals (primary), radiation oncology centers, and industrial/scientific institutions.

Recent strategic posture is offensive: opening the China QKM production facility in June 2026, launching commercial Ac-225 production in December 2024, spinning off PentixaPharm as a separate listed entity in October 2024, signing multiple supply and development agreements (Molecular Partners, SK Biopharmaceuticals, Bicycle Therapeutics, Actinium Pharmaceuticals, AtomVie, Archeus), and converting from AG to SE legal form in March 2024. Headcount exceeds 1,000 across Germany, the US, China, Brazil, and additional markets, with multi-year Deloitte Best Managed Companies recognition (2024-2026) and consecutive German vocational training quality awards.

Short descriptiontext

Eckert & Ziegler SE is a Berlin-based, TecDAX-listed isotope technology group producing medical radioisotopes (Ge-68/Ga-68, Lu-177, Ac-225, Y-90), brachytherapy implants, and radiopharmaceutical CDMO services for pharmaceutical, biotech, hospital, and industrial customers across Europe, the Americas, and Asia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBerlin, Germany
HQ citystring
Berlin
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical isotope production, radiopharmaceutical CDMO services, brachytherapy seeds, nuclear medicine imaging, industrial radiometry sources
Industry5 codes
PRIMARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAA
Diagnostic Radiopharmaceuticals (SPECT/PET Tracers)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAD
Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAIAGAE
Radiopharmacy Compounding & Dispensing (Hospital/Commercial)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAB
Industrial Isotope Production & Supply (Co-60, Ir-192, Cs-137, Am-241, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
NAICS code4 codes
  • Irradiation Apparatus Manufacturing334517
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code4 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Medicinal Chemicals & Botanical Products2833
  • Industrial Inorganic Chemicals2810
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Radiopharmaceuticals and Medical Isotopes
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Isotope Product Sales
TypeOne Time License
Description

Sale of medical isotopes including Germanium-68, Gallium-68, Lutetium-177, Actinium-225, Yttrium-90, Iodine-125, Ruthenium-106, and Krypton-85 to pharmaceutical companies, hospitals, and research institutions for diagnostics and therapy.

ezag.com
2Radiopharmaceutical CDMO Services
TypeProfessional Services
Description

Contract development and manufacturing of radiopharmaceutical products for clinical trials and commercial production, serving pharmaceutical partners across the globe. Includes GMP manufacturing suites and synthesis equipment such as Modular-Lab PharmTracer.

ezag.com
3Radiotherapy Devices and Implants
TypeHardware Sales
Description

Sale of brachytherapy seeds (I-125 for prostate cancer, Ru-106 for eye cancer), SagiNova tumor irradiation devices, and associated applicators for cancer treatment.

ezag.com
4Industrial Radiometry Products
TypeHardware Sales
Description

Supply of isotope-based industrial measurement and calibration products including Krypton-85 sources for thickness measurement and Nickel-63 sources for explosive/drug detection, as well as calibration sources for radioactivity measurement instruments.

ezag.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Operations, Infrastructure, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1GalliaPharm
Description

Ge-68/Ga-68 radionuclide generator product line for PET diagnostics

ezag.com
+2 more records
Core offering1 text field

Eckert & Ziegler manufactures and supplies medical isotopes (Germanium-68/Gallium-68, Lutetium-177, Actinium-225, Yttrium-90, Iodine-125) and brachytherapy products (prostate and ophthalmic seeds, Ru-106 eye applicators) for cancer therapy and diagnostics, and provides contract development and manufacturing (CDMO) services for radiopharmaceuticals. The company also produces industrial radiometry sources (Krypton-85, Nickel-63) and calibration sources for measurement, detection, and security applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 29% dividend increase from EUR 0.17 to EUR 0.22 per share for fiscal year 2025
+3 more records
Product overview1 text field

Eckert & Ziegler operates two main business segments: Medical (Radiopharma) and Isotope Products. The Medical segment encompasses radiopharmaceutical products and CDMO services, including GalliaPharm® Ge-68/Ga-68 generators, therapeutic isotopes (Lutetium-177, Actinium-225, Yttrium-90), and brachytherapy seeds (I-125 for prostate and eye cancer, Ru-106 eye applicators). The Isotope Products segment covers industrial radiometry applications including Krypton-85 for thickness measurement, Nickel-63 for security detection, and calibration sources. The company provides GMP manufacturing services for clinical trials and commercial radiopharmaceutical production across its global facilities in Germany, with recent expansion to China via the Qi Kang Medical Technology joint venture.

Product and service12 records
1GalliaPharm Ge-68/Ga-68 Radionuclide Generator
CategoryMedical isotope products
Description

Radioisotope generator producing Gallium-68 (Ga-68) for PET diagnostic imaging in nuclear medicine, including prostate cancer and neuroendocrine tumor diagnostics. Produced at the Berlin-Buch campus under GMP conditions.

2Lutetium-177
CategoryMedical isotope products
Description

Therapeutic beta-emitting radioisotope supplied in GMP quality for targeted radioligand therapies including neuroendocrine tumors and prostate cancer. Includes the Theralugand product with European approval.

3Actinium-225
CategoryMedical isotope products
Description

Alpha-emitting radioisotope used in targeted alpha therapy for next-generation cancer treatments, with production capabilities in Berlin and via the QKM joint venture in China.

4Yttrium-90
5I-125 Prostate Seeds
CategoryBrachytherapy products
Description

Radioactive iodine-125 seeds used for brachytherapy treatment of prostate cancer. Holds MDR certification for the European market.

6I-125 Ophthalmic Seeds
CategoryBrachytherapy products
Description

Radioactive iodine-125 seeds and COMS applicators for the treatment of eye cancers, particularly uveal melanoma.

7Ruthenium-106 Eye Applicators
CategoryBrachytherapy products
Description

Beta-emitting ruthenium-106 applicators used in brachytherapy for the treatment of eye tumors, maintained through MDR certification.

8Modular-Lab PharmTracer
CategoryRadiopharmaceutical manufacturing equipment
Description

Cassette-based synthesis device used by radiopharmaceutical manufacturing facilities to produce radioactively labeled compounds for clinical and commercial use.

9Krypton-85 Industrial Sources
CategoryIndustrial radiometry products
Description

Industrial isotope products using Krypton-85 for thickness measurement applications in manufacturing processes such as paper and metal production.

10Nickel-63 Detection Sources
CategoryIndustrial radiometry products
Description

Radioactive nickel-63 sources used in security industry applications including explosive detection and drug detection equipment.

11Calibration Sources
CategoryIndustrial radiometry products
Description

Calibration sources used to verify and validate radioactivity measurement devices in radiation protection, environmental monitoring, and laboratory settings.

12Radiopharmaceutical CDMO Services
CategoryRadiopharmaceutical manufacturing services
Description

Contract development and manufacturing organization (CDMO) services providing GMP manufacturing suites and capabilities for radiopharmaceutical clinical trial material and commercial production, including the production line for Modular-Lab PharmTracer synthesis devices.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-11
Description

Parity 50:50 joint venture Qi Kang Medical Technology (QKM) for production of medical isotopes in China. Located in Jintan district, Changzhou, with 9,500 m² facility. Phase 1 produces Ge-68 (mother isotope for Ga-68); Phase 2 plans first commercial Ac-225 production in China. Eckert & Ziegler contributes isotope production expertise; DC Pharma provides market access and regulatory knowledge in China.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-28
Description

Partnership announced on May 28, 2026, to expand production capabilities or technology access in the radiopharmaceutical sector.

Strategic tierMinorTypeOthersAnnounced on2026-05-28
Description

Morrison Foerster served as the organizer of the 4th Boston Radionuclide Theranostics Forum in 2026.

Strategic tierMinorTypeOthersAnnounced on2026-05-28
Description

Solomon Partners sponsored the 4th Boston Radionuclide Theranostics Forum organized by Eckert & Ziegler.

Strategic tierMinorTypeOthersAnnounced on2026-05-28
Description

German American Business Council of Boston provided organizational support for the 4th Boston Radionuclide Theranostics Forum.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-26
Description

Development agreement for Radio-DARPin therapeutics using Actinium-225 and Lutetium-177 payloads. Eckert & Ziegler provides manufacturing services from its facilities including the Alpha Laboratory in Berlin dedicated to alpha emitters. Partnership supports Molecular Partners' lead candidate MP0712 in Phase 1/2a trials for small cell lung cancer.

7SK Biopharmaceuticals Co., Ltd.
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-03
Description

Supply agreement for Actinium-225 (Ac-225), a critical isotope used in cancer therapies. This establishes a European supply base for SK, diversifying its supply network previously reliant on North American sources and ensuring stability amid limited global production.

koreaherald.com
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-07-29
Description

Eckert & Ziegler serves as US manufacturer for Archeus' next-generation radiopharmaceutical, expanding its role as a CDMO partner in the US market.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-24
Description

Manufacturing agreement for Yttrium-90-based PentixaTher radiopharmaceutical. Eckert & Ziegler holds majority stake in PentixaPharm, which was spun off as a separate listed entity and is developing CXCR4-targeted radiopharmaceuticals for hematologic malignancies and solid tumors.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-03-25
Description

Supply of Actinium-225 for Actinium Pharmaceuticals' comprehensive clinical program in targeted alpha therapy for various cancers.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-03-20
Description

Worldwide agreement for radiopharmaceutical manufacturing and supply services, expanding Eckert & Ziegler's CDMO footprint globally.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-27
Description

Strategic partnership for development and manufacturing of Bicycle Radioconjugates using therapeutic radioisotopes. Eckert & Ziegler provides manufacturing capabilities for radiolabeling of Bicycle's targeted radiotherapy candidates.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-12-05
Description

Global supply agreement for medical isotopes supporting Ariceum's PSMA-targeted diagnostic and therapeutic radiopharmaceutical programs for cancer. Ariceum acquired Theragnostics Ltd in June 2023 to strengthen its PSMA kit portfolio.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-11-13
Description

Cooperation and license agreement for Illuccix PSMA-PET diagnostics. Eckert & Ziegler supports manufacturing and distribution of the diagnostic kit in Germany, leveraging its radiopharmaceutical CDMO capabilities and regulatory approvals in the German market.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-19
Description

Partnership to significantly increase Actinium-225 production volume. The new production facility opened in June 2024 and represents a major expansion of alpha emitter manufacturing capacity in Europe, with UJF contributing research infrastructure and Eckert & Ziegler providing commercial production capabilities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-01-31
Description

Supply agreement for therapeutic radioisotopes including Lutetium-177 for Nucleus Radiopharma's radiopharmaceutical development pipeline.

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Cardinal Health operates a nuclear pharmacy services network distributing radiopharmaceuticals to US hospitals. While not a direct manufacturer, it operates in the same nuclear medicine distribution channel that E&Z supplies into, making it a channel-adjacent peer.

TypeBroad incumbent
Description

GE HealthCare operates a large radiopharmacy network (PETNET) and supplies imaging agents including Ga-68 generators, plus broader imaging equipment. It overlaps with E&Z in nuclear medicine imaging supply but operates at far broader scale across the imaging value chain.

TypeDirect peer
Description

Lantheus is a US-based radiopharmaceutical-focused company with diagnostic imaging products (e.g., Pylarify PSMA-PET). It overlaps with E&Z's diagnostic radiopharma franchise and competes for nuclear medicine supply contracts.

TypeBroad incumbent
Description

Bayer's radiology business (legacy Medrad/Mallinckrodt) develops contrast and radiopharmaceutical agents including Xofigo (Ra-223). As a major life sciences player it competes broadly with E&Z in alpha-emitting therapeutics and nuclear medicine.

TypeEmerging player
Description

Nucleus Radiopharma is a US-based CDMO building dedicated radiopharmaceutical manufacturing capacity, including Lu-177. It is both an E&Z customer (Lu-177 supply) and an emerging competitor in CDMO services.

TypeDirect peer
Description

Curium is one of the world's largest nuclear medicine companies producing diagnostic and therapeutic radiopharmaceuticals (Mo-99/Tc-99m, I-131, Lu-177). It directly overlaps E&Z's radiopharma CDMO and isotope production business across nuclear medicine customers.

TypeDirect peer
Description

ITM is a German radiopharmaceutical company producing high-purity Lu-177 and other medical isotopes for cancer therapy. It directly competes with E&Z in Lu-177 supply and is also developing Ac-225 - a head-to-head competitor in the same geography.

TypeDirect peer
Description

Telix develops and commercializes therapeutic and diagnostic radiopharmaceuticals (Illuccix PSMA-PET). The firm is both an E&Z customer (manufacturing/distribution deal in Germany) and a direct competitor in commercial radiopharmaceutical products.

TypeEmerging player
Description

NorthStar produces Mo-99 domestically in the US without relying on legacy reactor sources, expanding into Cu-64, Cu-67, and other therapeutic isotopes. It is an emerging competitor in isotope production where E&Z also participates.

TypeEmerging player
Description

AtomVie is a Canadian radiopharmaceutical CDMO spun out from the Centre for Probe Development and Commercialization, offering GMP manufacturing for radiopharmaceuticals. It is both an E&Z partner (worldwide supply agreement) and an emerging CDMO competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers15 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eckert & Ziegler

Radiopharmaceuticals and Medical Isotopesezag.com

Eckert & Ziegler SE is a Berlin-based, TecDAX-listed isotope technology group producing medical radioisotopes (Ge-68/Ga-68, Lu-177, Ac-225, Y-90), brachytherapy implants, and radiopharmaceutical CDMO services for pharmaceutical, biotech, hospital, and industrial customers across Europe, the Americas, and Asia.

What Eckert & Ziegler does

Eckert & Ziegler SE is a Berlin-headquartered, TecDAX-listed (Deutsche Börse, ISIN DE0005659700) isotope technology group operating across medical, scientific, and industrial end-markets. The company's core capabilities span the radioisotope value chain — production of medical isotopes including Germanium-68, Gallium-68, Lutetium-177, Actinium-225, and Yttrium-90, alongside brachytherapy implants (I-125 prostate and ophthalmic seeds, Ru-106 eye applicators) and industrial radiometry products (Kr-85 thickness sources, Ni-63 detection sources, calibration sources). Its technology platform centers on a dedicated Alpha Laboratory in Berlin for Actinium-225, the proprietary GalliaPharm Ge-68/Ga-68 generator system, GMP-compliant radiopharmaceutical manufacturing suites, the Modular-Lab PharmTracer synthesis platform, and cyclotron-based production at the Berlin-Buch, Braunschweig, and Jintan (China, via 50:50 JV QKM with DC Pharma) sites.

The business generates revenue through three primary streams: (i) one-time sales of isotope products to pharmaceutical companies, hospitals, and research institutions; (ii) contract development and manufacturing (CDMO) services for radiopharmaceuticals, supplied under quote-based B2B contracts to clients including Molecular Partners, SK Biopharmaceuticals, Ariceum, Bicycle Therapeutics, Telix, and PentixaPharm; and (iii) hardware sales of brachytherapy devices and industrial radiometry products. Go-to-market is enterprise field sales complemented by industry engagement such as the annual Boston Radionuclide Theranostics Forum. The customer base is horizontally segmented into pharmaceutical/biotech companies (primary), nuclear medicine departments and hospitals (primary), radiation oncology centers, and industrial/scientific institutions.

Recent strategic posture is offensive: opening the China QKM production facility in June 2026, launching commercial Ac-225 production in December 2024, spinning off PentixaPharm as a separate listed entity in October 2024, signing multiple supply and development agreements (Molecular Partners, SK Biopharmaceuticals, Bicycle Therapeutics, Actinium Pharmaceuticals, AtomVie, Archeus), and converting from AG to SE legal form in March 2024. Headcount exceeds 1,000 across Germany, the US, China, Brazil, and additional markets, with multi-year Deloitte Best Managed Companies recognition (2024-2026) and consecutive German vocational training quality awards.

Eckert & Ziegler firmographics

Firmographics
Name
Eckert & Ziegler
Legal name
Eckert & Ziegler SE
Website
https://ezag.com
Company type
Public
Founded year
1998
Operating status
Operating
Headcount range
251–500 employees
Short description
Eckert & Ziegler SE is a Berlin-based, TecDAX-listed isotope technology group producing medical radioisotopes (Ge-68/Ga-68, Lu-177, Ac-225, Y-90), brachytherapy implants, and radiopharmaceutical CDMO services for pharmaceutical, biotech, hospital, and industrial customers across Europe, the Americas, and Asia.
Ownership category
akta.pro rank

Eckert & Ziegler industry classification

Industry
Product category
Radiopharmaceuticals and Medical Isotopes
NAICS
Irradiation Apparatus Manufacturing (334517), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Medicinal Chemicals & Botanical Products (2833), Industrial Inorganic Chemicals (2810), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAA
Diagnostic Radiopharmaceuticals (SPECT/PET Tracers)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAD
Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAIAGAE
Radiopharmacy Compounding & Dispensing (Hospital/Commercial)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAB
Industrial Isotope Production & Supply (Co-60, Ir-192, Cs-137, Am-241, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)

Keywords

  • Medical isotope production
  • Radiopharmaceutical CDMO services
  • Brachytherapy seeds
  • Nuclear medicine imaging
  • Industrial radiometry sources

Where Eckert & Ziegler is headquartered

Location

Headquarters

HQ city
Berlin
HQ country
Germany
HQ region
Europe

Offices5 records

Markets served

Eckert & Ziegler business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Operations, Infrastructure, Personnel, Marketing or Sales

Revenue model

  1. Isotope Product Sales: Sale of medical isotopes including Germanium-68, Gallium-68, Lutetium-177, Actinium-225, Yttrium-90, Iodine-125, Ruthenium-106, and Krypton-85 to pharmaceutical companies, hospitals, and research institutions for diagnostics and therapy.
  2. Radiopharmaceutical CDMO Services: Contract development and manufacturing of radiopharmaceutical products for clinical trials and commercial production, serving pharmaceutical partners across the globe. Includes GMP manufacturing suites and synthesis equipment such as Modular-Lab PharmTracer.
  3. Radiotherapy Devices and Implants: Sale of brachytherapy seeds (I-125 for prostate cancer, Ru-106 for eye cancer), SagiNova tumor irradiation devices, and associated applicators for cancer treatment.
  4. Industrial Radiometry Products: Supply of isotope-based industrial measurement and calibration products including Krypton-85 sources for thickness measurement and Nickel-63 sources for explosive/drug detection, as well as calibration sources for radioactivity measurement instruments.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Eckert & Ziegler product offering

Product offering

Core offering

Eckert & Ziegler manufactures and supplies medical isotopes (Germanium-68/Gallium-68, Lutetium-177, Actinium-225, Yttrium-90, Iodine-125) and brachytherapy products (prostate and ophthalmic seeds, Ru-106 eye applicators) for cancer therapy and diagnostics, and provides contract development and manufacturing (CDMO) services for radiopharmaceuticals. The company also produces industrial radiometry sources (Krypton-85, Nickel-63) and calibration sources for measurement, detection, and security applications.

Product overview

Eckert & Ziegler operates two main business segments: Medical (Radiopharma) and Isotope Products. The Medical segment encompasses radiopharmaceutical products and CDMO services, including GalliaPharm® Ge-68/Ga-68 generators, therapeutic isotopes (Lutetium-177, Actinium-225, Yttrium-90), and brachytherapy seeds (I-125 for prostate and eye cancer, Ru-106 eye applicators). The Isotope Products segment covers industrial radiometry applications including Krypton-85 for thickness measurement, Nickel-63 for security detection, and calibration sources. The company provides GMP manufacturing services for clinical trials and commercial radiopharmaceutical production across its global facilities in Germany, with recent expansion to China via the Qi Kang Medical Technology joint venture.

Differentiator

Problem solved

Functional benefit

Brands

  • GalliaPharm: Ge-68/Ga-68 radionuclide generator product line for PET diagnostics
  • Theralugand
  • Modular-Lab PharmTracer

Products and services

  • GalliaPharm Ge-68/Ga-68 Radionuclide Generator Radioisotope generator producing Gallium-68 (Ga-68) for PET diagnostic imaging in nuclear medicine, including prostate cancer and neuroendocrine tumor diagnostics. Produced at the Berlin-Buch campus under GMP conditions.
  • Lutetium-177 Therapeutic beta-emitting radioisotope supplied in GMP quality for targeted radioligand therapies including neuroendocrine tumors and prostate cancer. Includes the Theralugand product with European approval.
  • Actinium-225 Alpha-emitting radioisotope used in targeted alpha therapy for next-generation cancer treatments, with production capabilities in Berlin and via the QKM joint venture in China.
  • Yttrium-90
  • I-125 Prostate Seeds Radioactive iodine-125 seeds used for brachytherapy treatment of prostate cancer. Holds MDR certification for the European market.
  • I-125 Ophthalmic Seeds Radioactive iodine-125 seeds and COMS applicators for the treatment of eye cancers, particularly uveal melanoma.
  • Ruthenium-106 Eye Applicators Beta-emitting ruthenium-106 applicators used in brachytherapy for the treatment of eye tumors, maintained through MDR certification.
  • Modular-Lab PharmTracer Cassette-based synthesis device used by radiopharmaceutical manufacturing facilities to produce radioactively labeled compounds for clinical and commercial use.
  • Krypton-85 Industrial Sources Industrial isotope products using Krypton-85 for thickness measurement applications in manufacturing processes such as paper and metal production.
  • Nickel-63 Detection Sources Radioactive nickel-63 sources used in security industry applications including explosive detection and drug detection equipment.
  • Calibration Sources Calibration sources used to verify and validate radioactivity measurement devices in radiation protection, environmental monitoring, and laboratory settings.
  • Radiopharmaceutical CDMO Services Contract development and manufacturing organization (CDMO) services providing GMP manufacturing suites and capabilities for radiopharmaceutical clinical trial material and commercial production, including the production line for Modular-Lab PharmTracer synthesis devices.

Quantifiable outcome

  • 29% dividend increase from EUR 0.17 to EUR 0.22 per share for fiscal year 2025
  • +3 more outcomes

Companies that use Eckert & Ziegler

Customer profile

Named customers15 records

Segments4 records

Ideal customer profiles3 records

Eckert & Ziegler technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Eckert & Ziegler partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered core and minor.

  • DongCheng Pharma (DC Pharma) / Qi Kang Medical Technology (QKM)coreStrategic or Co-development Partner · 11 June 2026Parity 50:50 joint venture Qi Kang Medical Technology (QKM) for production of medical isotopes in China. Located in Jintan district, Changzhou, with 9,500 m² facility. Phase 1 produces Ge-68 (mother isotope for Ga-68); Phase 2 plans first commercial Ac-225 production in China. Eckert & Ziegler contributes isotope production expertise; DC Pharma provides market access and regulatory knowledge in China.
  • Thor MedicalminorStrategic or Co-development Partner · 28 May 2026Partnership announced on May 28, 2026, to expand production capabilities or technology access in the radiopharmaceutical sector.
  • Morrison Foerster (Legal Counsel)minorOthers · 28 May 2026Morrison Foerster served as the organizer of the 4th Boston Radionuclide Theranostics Forum in 2026.
  • Solomon Partners (Sponsor)minorOthers · 28 May 2026Solomon Partners sponsored the 4th Boston Radionuclide Theranostics Forum organized by Eckert & Ziegler.
  • German American Business Council of BostonminorOthers · 28 May 2026German American Business Council of Boston provided organizational support for the 4th Boston Radionuclide Theranostics Forum.
  • Molecular Partners AGcoreStrategic or Co-development Partner · 26 February 2026Development agreement for Radio-DARPin therapeutics using Actinium-225 and Lutetium-177 payloads. Eckert & Ziegler provides manufacturing services from its facilities including the Alpha Laboratory in Berlin dedicated to alpha emitters. Partnership supports Molecular Partners' lead candidate MP0712 in Phase 1/2a trials for small cell lung cancer.
  • SK Biopharmaceuticals Co., Ltd.coreTechnology or Integration · 3 December 2025Supply agreement for Actinium-225 (Ac-225), a critical isotope used in cancer therapies. This establishes a European supply base for SK, diversifying its supply network previously reliant on North American sources and ensuring stability amid limited global production.
  • ArcheusminorChannel Partner/ Reseller/ Distributor · 29 July 2025Eckert & Ziegler serves as US manufacturer for Archeus' next-generation radiopharmaceutical, expanding its role as a CDMO partner in the US market.
  • PentixaPharm AGcoreStrategic or Co-development Partner · 24 April 2025Manufacturing agreement for Yttrium-90-based PentixaTher radiopharmaceutical. Eckert & Ziegler holds majority stake in PentixaPharm, which was spun off as a separate listed entity and is developing CXCR4-targeted radiopharmaceuticals for hematologic malignancies and solid tumors.
  • Actinium PharmaceuticalscoreTechnology or Integration · 25 March 2025Supply of Actinium-225 for Actinium Pharmaceuticals' comprehensive clinical program in targeted alpha therapy for various cancers.
  • AtomVie Global RadiopharmacoreChannel Partner/ Reseller/ Distributor · 20 March 2025Worldwide agreement for radiopharmaceutical manufacturing and supply services, expanding Eckert & Ziegler's CDMO footprint globally.
  • Bicycle TherapeuticscoreStrategic or Co-development Partner · 27 February 2025Strategic partnership for development and manufacturing of Bicycle Radioconjugates using therapeutic radioisotopes. Eckert & Ziegler provides manufacturing capabilities for radiolabeling of Bicycle's targeted radiotherapy candidates.
  • Ariceum Therapeutics GmbHcoreTechnology or Integration · 5 December 2024Global supply agreement for medical isotopes supporting Ariceum's PSMA-targeted diagnostic and therapeutic radiopharmaceutical programs for cancer. Ariceum acquired Theragnostics Ltd in June 2023 to strengthen its PSMA kit portfolio.
  • Telix PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 13 November 2024Cooperation and license agreement for Illuccix PSMA-PET diagnostics. Eckert & Ziegler supports manufacturing and distribution of the diagnostic kit in Germany, leveraging its radiopharmaceutical CDMO capabilities and regulatory approvals in the German market.
  • UJF (Ústav jaderné fyziky AV ČR)coreStrategic or Co-development Partner · 19 June 2024Partnership to significantly increase Actinium-225 production volume. The new production facility opened in June 2024 and represents a major expansion of alpha emitter manufacturing capacity in Europe, with UJF contributing research infrastructure and Eckert & Ziegler providing commercial production capabilities.
  • Nucleus RadiopharmacoreTechnology or Integration · 31 January 2024Supply agreement for therapeutic radioisotopes including Lutetium-177 for Nucleus Radiopharma's radiopharmaceutical development pipeline.

Scale indicators9 records

Recent moves12 records

Expansion highlights7 records

Eckert & Ziegler competitors and assessment

Company assessment

Others

  • Cardinal Health (Radiopharmaceutical Distribution): Cardinal Health operates a nuclear pharmacy services network distributing radiopharmaceuticals to US hospitals. While not a direct manufacturer, it operates in the same nuclear medicine distribution channel that E&Z supplies into, making it a channel-adjacent peer.

Broad incumbents

  • GE HealthCare: GE HealthCare operates a large radiopharmacy network (PETNET) and supplies imaging agents including Ga-68 generators, plus broader imaging equipment. It overlaps with E&Z in nuclear medicine imaging supply but operates at far broader scale across the imaging value chain.
  • Bayer (Radiology / Curium JV): Bayer's radiology business (legacy Medrad/Mallinckrodt) develops contrast and radiopharmaceutical agents including Xofigo (Ra-223). As a major life sciences player it competes broadly with E&Z in alpha-emitting therapeutics and nuclear medicine.

Direct peers

  • Lantheus Holdings: Lantheus is a US-based radiopharmaceutical-focused company with diagnostic imaging products (e.g., Pylarify PSMA-PET). It overlaps with E&Z's diagnostic radiopharma franchise and competes for nuclear medicine supply contracts.
  • Curium Pharma: Curium is one of the world's largest nuclear medicine companies producing diagnostic and therapeutic radiopharmaceuticals (Mo-99/Tc-99m, I-131, Lu-177). It directly overlaps E&Z's radiopharma CDMO and isotope production business across nuclear medicine customers.
  • ITM Isotope Technologies Munich: ITM is a German radiopharmaceutical company producing high-purity Lu-177 and other medical isotopes for cancer therapy. It directly competes with E&Z in Lu-177 supply and is also developing Ac-225 - a head-to-head competitor in the same geography.
  • Telix Pharmaceuticals: Telix develops and commercializes therapeutic and diagnostic radiopharmaceuticals (Illuccix PSMA-PET). The firm is both an E&Z customer (manufacturing/distribution deal in Germany) and a direct competitor in commercial radiopharmaceutical products.

Emerging players

  • Nucleus Radiopharma: Nucleus Radiopharma is a US-based CDMO building dedicated radiopharmaceutical manufacturing capacity, including Lu-177. It is both an E&Z customer (Lu-177 supply) and an emerging competitor in CDMO services.
  • NorthStar Medical Radioisotopes: NorthStar produces Mo-99 domestically in the US without relying on legacy reactor sources, expanding into Cu-64, Cu-67, and other therapeutic isotopes. It is an emerging competitor in isotope production where E&Z also participates.
  • AtomVie Global Radiopharma: AtomVie is a Canadian radiopharmaceutical CDMO spun out from the Centre for Probe Development and Commercialization, offering GMP manufacturing for radiopharmaceuticals. It is both an E&Z partner (worldwide supply agreement) and an emerging CDMO competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Eckert & Ziegler social profiles

Digital presence

Eckert & Ziegler compliance and trust

Trust signal

Compliance6 records

Eckert & Ziegler financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eckert & Ziegler leadership team

Management profile

Number of profiles

Profiles2 records

Eckert & Ziegler subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Eckert & Ziegler funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eckert & Ziegler M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eckert & Ziegler

What does Eckert & Ziegler do?

Eckert & Ziegler manufactures and supplies medical isotopes (Germanium-68/Gallium-68, Lutetium-177, Actinium-225, Yttrium-90, Iodine-125) and brachytherapy products (prostate and ophthalmic seeds, Ru-106 eye applicators) for cancer therapy and diagnostics, and provides contract development and manufacturing (CDMO) services for radiopharmaceuticals. The company also produces industrial radiometry sources (Krypton-85, Nickel-63) and calibration sources for measurement, detection, and security applications.

Is Eckert & Ziegler a public or private company?

Eckert & Ziegler is a public company. It is classified as public and is currently operating.

When was Eckert & Ziegler founded?

Eckert & Ziegler was founded in 1998. It employs 251 to 500 people.

Where is Eckert & Ziegler based?

Eckert & Ziegler is headquartered in Berlin, Germany, in the Europe region.

How does Eckert & Ziegler make money?

Four revenue lines are on record. Isotope Product Sales are the primary driver. The others are radiopharmaceutical CDMO Services, radiotherapy Devices and Implants and industrial Radiometry Products.

Who are Eckert & Ziegler's main competitors?

Cardinal Health (Radiopharmaceutical Distribution) is listed as an others. Broad incumbents are GE HealthCare and Bayer (Radiology / Curium JV). Direct peers are Lantheus Holdings, Curium Pharma, ITM Isotope Technologies Munich and Telix Pharmaceuticals. Emerging players are Nucleus Radiopharma, NorthStar Medical Radioisotopes and AtomVie Global Radiopharma.

Does Eckert & Ziegler have an API?

No public API is recorded for Eckert & Ziegler.

What industry is Eckert & Ziegler in?

Eckert & Ziegler's product category is Radiopharmaceuticals and Medical Isotopes. Its primary akta.pro industry code is HLAIAGAD, Radioisotope Production (Reactor/Cyclotron/Gamma), with a secondary code of HLAIAGAA, Diagnostic Radiopharmaceuticals (SPECT/PET Tracers). Its NAICS code is 334517 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StHere's What Analysts Are Forecasting For Eckert & Ziegler SE (ETR:EUZ) After Its First-Quarter ResultsEckert & Ziegler reported Q1 revenues of €73m and EPS of €0.78, in line with analyst expectations. Analysts forecast 2026 revenues of €318.7m and EPS of €0.82, with a consensus price target of €21.93. Revenue growth is expected to slow to 0.8% annually, below the industry average of 5.6%.FinanzNachrichten.deQ3 review: a stronger dose of earnings: EUZ's Q3 earnings recovery provides a firmer base for year-end ...Eckert & Ziegler reported Q3 sales of €79.6m and adjusted EBIT of €19.3m, up 6% and 25% year-over-year. Medical segment sales rose 4% to €40.6m, with Lu-177 sales up 280% year-over-year. The company expects Q4 licence income of €3-5.6m, below Q4 2025's €9.4m.EuropaWireEckert & Ziegler lifts third-quarter adjusted EBIT by 25% and maintains 2026 earnings outlookEckert & Ziegler reported Q3 2026 sales of €79.6 million and adjusted EBIT of €19.3 million, a 25% increase. Nine-month net income rose 19% to €35.4 million, and the company confirmed 2026 guidance of about €320 million in sales and €80 million in adjusted EBIT.PR NewswirePentixapharm Holding AG extends drawdown period and term of its convertible bond with Eckert & Ziegler SE to 2030 with adjusted termsPentixapharm Holding AG amended its 4.00% convertible bond with Eckert & Ziegler SE, extending the term to 31 December 2030 and raising the interest rate to 6.00% p.a. from 1 January 2027. The amendment increases financial flexibility by deferring repayment of EUR 5.0 million and allowing further drawdowns until mid-2030.The future of tradingEckert & Ziegler Confirms 2026 ForecastEckert & Ziegler confirmed its 2026 forecast, projecting sales around €320 million and adjusted EBIT near €80 million. The company also raised its Q3 2026 adjusted EBIT to €19.30 million from €15.40 million and net income to €13.10 million from €8.50 million.Business & FinancialEckert & Ziegler: Adjusted EBIT +25% In The Third Quarter. 2026 Forecast ConfirmedEckert & Ziegler reported adjusted EBIT up 25% to €52.6 million in the first nine months of 2026, with sales at €229.0 million. The company confirmed its 2026 forecast of €320 million in sales and €80 million in adjusted EBIT, expecting license revenues in the fourth quarter.TradingViewEUZ: Underlying growth accelerated, led by Medical, and FY 2026 guidance was reaffirmedEckert & Ziegler reported 9M revenue of €229.0 million, up 4% excluding prior-year licensing, and adjusted EBIT grew 14% on the same basis. Medical and radioisotope growth offset weaker industrial demand and product mix, and the company reaffirmed its FY 2026 guidance.EuropaWireEckert & Ziegler Gains GMP Manufacturing Authorisation for Actinium-225 in GermanyEckert & Ziegler Therapeutics received German GMP manufacturing authorisation for Actinium-225, enabling GMP-grade production for investigational use. The process irradiates Radium-226 in Czech Republic and processes it in Germany, with plans for commercial-scale production in China starting early 2027.FinanzNachrichten.deEckert & Ziegler erhält Herstellungserlaubnis für Actinium-225Eckert & Ziegler received a production license for Actinium-225 under GMP standards, with the German authority confirming quality compliance. The body also includes a separate oil crisis report promoting five stocks, unrelated to the license.Business & FinancialEckert & Ziegler Receives GMP Certificate For Actinium-225Eckert & Ziegler's subsidiary received a German GMP certificate for Actinium-225, enabling its use in investigational treatments. The company plans to expand capacity in Asia and North America, with a joint venture in China set to become the first commercial-scale Ac-225 production site in 2027.